

1 **Modafinil for Wakefulness in the Critical Care Units: A Literature Review and Case Series including**

2 **COVID-19 Patients at a Tertiary Care Saudi Hospital**

3

4 **Marwa Amer, PharmD, B.S. Pharm, BCPS, BCCCP ***

5 Critical Care Pharmacy Specialist, Medical and Surgical ICU

6 Adjunct Assistant Professor- Alfaisal University- College of Medicine

7 Pharmaceutical Care Division, MBC # 11

8 King Faisal Specialist Hospital & Research Center

9 P. O. Box 3354, Riyadh, 11211

10 Tel: +966114647272, Extension: 48030

11 Email address: mamer@kfshrc.edu.sa

12 Fax number: +966-11-4424184

13

14 **Mohammed Bawazeer MD, FRCSC, FACS**

15 Trauma & Acute Care Surgery

16 Consultant Intensivist

17 Medical Director, Surgical Critical Care Unit

18 Founder and Head of the Surgical Critical Care Chapter, Saudi Critical Care Society

19 Department of Critical Care Medicine (MBC 94)

20 King Faisal Specialist Hospital & Research Centre

21 Email address: mbawazeer@kfshrc.edu.sa

22

23 **Abid Shahzad Butt, MD**

24 Consultant Intensivist

25 Department of Critical Care Medicine (MBC 94)

26 King Faisal Specialist Hospital & Research Centre

27 Email address: asbutt@kfshrc.edu.sa

28

29 **Talal I. Dahhan, MD, MMEL,**

30 Assistant Professor, Alfaisal University, College of Medicine

31 Consultant, Critical Care and Pulmonary Vascular Diseases

32 Critical Care Fellowship Training Program Director

33 Performance Improvement Director

34 Department of Critical Care Medicine (MBC 94)

35 King Faisal Specialist Hospital & Research Centre

36 Email: tdahhan@kfshrc.edu.sa

37 Education Lead

38 Division of Pulmonary, Allergy and Critical Care Medicine

39 Department of Medicine

40 Duke University Durham, NC, United States

41 Email: talal.dahhan@duke.edu

42

43 **Eiad Kseibi, MD**

44 Consultant Intensivist

45 Department of Critical Care Medicine (MBC 94)

46 King Faisal Specialist Hospital & Research Centre

47 Email address: ekseibi6@kfshrc.edu.sa

48

49 **Mouhamad Ghyath Jamil M.D., FCCP**

50 Pulmonary/CCM/sleep Medicine

51 Section Head Sleep Medicine

52 Director Tele-ICU

53 Department of Critical Care Medicine (MBC 94)

54 King Faisal Specialist Hospital & Research Centre

55 Email address: mjamil@kfshrc.edu.sa

56 *Corresponding author at: King Faisal Specialist Hospital & Research Center, Pharmaceutical Care

57 Division (MBC # 11), PO Box 3354, Riyadh, 11211, Tel: +966114647272 Ext 70836 or 48030

58 Email address: mamer@kfshrc.edu.sa

59

60

1 **Modafinil for Wakefulness in the Critical Care Units: A Case Series including COVID-19 Patients at a**
2 **Tertiary Care Saudi Hospital**

3 Marwa Amer ^{a,b*}, Mohammed Bawazeer ^c, Abid Butt ^c, Talal Dahhan ^{b,c}, Eiad Kseibi ^c, Mouhamad Ghyath
4 Jamil ^c

5 ^a Pharmaceutical Care Division, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi
6 Arabia

7 ^b College of Medicine, Alfaisal University

8 ^c Department of Critical Care Medicine, King Faisal Specialist Hospital and Research Center, Riyadh,
9 Saudi Arabia

10

11

12

13

14

15

16

17

18

19

20

21

22

23 **Abstract**

24 Cognitive improvement after critical illness is complex. Neuro-stimulants are used to speed up physical
25 and mental processes through the increase in arousal, and wakefulness. In this case series, we reviewed
26 the literature and described the effect of modafinil for wakefulness in a cohort of adult patients admitted
27 to our COVID and non-COVID intensive care unit (ICU) between January 2017 and June 2020. A total of 8
28 patients included; 3 admitted to COVID-19, 4 surgical, and 1 transplant ICU. Obstructive sleep apnea was
29 noted in 2 (25%), 2 patients (25 %) had an initial neuroimaging that showed hemorrhagic stroke, and 1
30 (12.5%) showed ischemic stroke with hemorrhagic transformation. Modafinil 100-200 mg daily was
31 started for a median duration of 4 days and the median initiation time in relation to ICU admission was 11
32 (IQR 9-17) days. Glasgow coma Scale improvement was noted on 5 patients (62.5%). The median duration
33 of mechanical ventilation was 17.5 (IQR 15-31.75) days, and the median ICU stay was 28.5 (IQR 20.25-48)
34 days. All-cause mortality rate was 25 % at 28 days and 62.5 % at 90 days. Modafinil prevented
35 tracheostomy in 1 COVID-19 patient. No significant adverse drug reactions were documented. In our case
36 series, we described our experience for modafinil use for wakefulness in ICU ventilated patients including
37 COVID-19 patients. Based on our observations, the known effects of modafinil, and its safety profile, it
38 holds the potential to facilitate recovery from cognitive impairment. Larger studies are warranted to fully
39 evaluate its role for this indication.

40 **Keywords:** Modafinil, neurostimulant, critical care, COVID-19, mechanical ventilation

41 **Word count:** abstract: 250 words, main text: 4210 words, references: 45, keywords: 5

42

43

44

45

46

47

48

49 **1. Introduction**

50 Intensive care unit (ICU) patients are susceptible to neurocognitive and musculoskeletal complications
51 because of various factors, such as the nature of critical illness, medications, over-sedation, and pain [1].
52 Moreover, sleep disruption in ICUs remains an elusive and pervasive problem. The 2018 pain, agitation/ sedation,
53 delirium, immobility, and sleep disruption (PADIS) guidelines included a brief overview of risk factors contributing
54 to disrupted sleep quality (e.g., architecture, fragmentation, sleep quality score), quantity (e.g., latency, and
55 duration), or circadian rhythm in ICUs [2,3]. Additionally, clinical experience from severe acute respiratory
56 syndrome coronavirus 2 (SARS-CoV-2) suggests its neuro-invasive potential [4-6]. Approximately 36.4%
57 coronavirus disease 2019 (COVID-19) inpatients in a Wuhan hospital exhibited neurological signs and/or
58 symptoms during infection [7]. Manifestations included delirium, confusion, executive dysfunction, anosmia,
59 stroke, headache, Guillain Barré syndrome (GBS), Miller Fisher syndrome, encephalitis, acute necrotizing
60 encephalopathy, myelitis and CNS demyelinating lesions [7,8]. Moreover, critical illness polyneuropathy and ICU-
61 acquired weakness have been observed in 25-46% of ICU patients. Duration of ventilation, corticosteroid
62 administration, multi-organ dysfunction, sepsis, hyperglycemia, and renal replacement therapy have all been
63 correlated with ICU-acquired weakness [9-11]. However, their incidence is unknown in patients with SARS-CoV-
64 2 infection. Case reports of critical-illness polyneuropathy and/or myopathy are rare in patients with SARS-CoV-
65 1 and Middle East respiratory syndrome (MERS-CoV), which can be attributed to the low number of correlation
66 studies between these illnesses and the prolonged ICU stay [12,13].

67 Early mobilization of these patients has become the standard of care; however, somnolent, fatigued, and
68 depressed patients may not be able or willing to comply and may have a delayed recovery [3]. Neuro-stimulants
69 are used to speed up the physical and mental processes through the increase of dopamine, serotonin,
70 norepinephrine, and acetylcholine. This in turn translates to improved neuro-cognition, enhanced arousal,
71 wakefulness, attention, memory, mental, and motor processing speed [14]. Although, the prescribing trends of
72 neuro-stimulants are yet to be fully elucidated, their use is increasing in traumatic brain injury (TBI) patients

73 especially those with coma, vegetative state (VS), or minimally conscious state (MCS). Neuro-stimulants are
74 sometimes prescribed for off label use, to help in arousal and promote wakefulness in ICUs. The clinical rationale
75 is to facilitate transition from VS, and increase participation in physiotherapy and ambulation, thereby,
76 decreasing ICU-related complications such as deep vein thrombosis (DVT), and ICU-acquired delirium, while
77 facilitating self-expression, accelerating recovery, hastening liberation from the ventilatory support, and
78 decreasing ICU length of stay. Selected neuro-stimulants use in neuro-ICU are summarized at **Table S1** [14-25].

79 Modafinil is approved by US Food and Drug Administration (FDA) for narcolepsy, obstructive sleep apnea,
80 and shift work sleep disorder. Although the mechanism of action of modafinil remains uncertain, its cognition
81 enhancing properties are attributed to the modulation of glutamate, gamma-aminobutyric acid (GABA) and
82 alpha1B noradrenergic receptors while it has minimal effect on serotonin [26]. Modafinil also offers several
83 advantages over other conventional neuro-stimulants as it does not exhibit the same level of sympathomimetic
84 effects, such as behavioral excitation or rebound hypersomnolence, suggesting that its mechanism of action is
85 distinct. It also has a minimal potential for abuse, and does not appear to disrupt normal sleep architecture. Its
86 favorable safety profile makes it an attractive agent for use in critically ill patients. Side effects include insomnia,
87 anxiety, and cataplexy. At our institution, modafinil is approved for improving wakefulness in adults with
88 excessive daytime sleepiness (EDS) associated with narcolepsy and idiopathic hypersomnia, shift work sleep
89 disorder and as an adjunctive therapy for obstructive sleep apnea (OSA)/hypopnea syndrome. Prescribing
90 privilege is restricted to neurologists, psychiatrists, and sleep medicine consultants. The efficacy of modafinil on
91 wakefulness has been studied in TBI and post-stroke patients [17, 27-32] [**Table 1**]. In ICU setting, a case series
92 by Gajewski and colleagues demonstrated clinical improvement after the start of modafinil therapy in 3 non-
93 intubated ICU patients [31]. A retrospective cohort study by Yoonsun *et al* evaluated whether modafinil improved
94 cognitive function for ICU patients by promoting wakefulness [32]. A total of 60 patients required ventilatory
95 support at a 336-bed community hospital were included. Modafinil resulted in small, nonsignificant increase in
96 Glasgow Coma Scale (GCS) by 0.34 points after controlling for age, baseline severity of illness, and changes in
97 sedation and analgesia over time (95% CI, -0.34 to 0.73 points; p = 0.0743). There was a reduction in exposure

98 to sedatives and analgesics after modafinil was started, resulting in an increasing trend of GCS over time. No
99 major adverse effects were observed. The authors concluded that modafinil did prove beneficial in promoting
100 wakefulness in ICU patients. Its impact on overall patient outcomes in the ICU remains unclear and needs further
101 investigation. In order to gain insight on modafinil use for wakefulness in ICU, we reviewed the literature,
102 described 8 patients, and provided additional clinical data about COVID-19 cases admitted to the ICU. Our aim to
103 describe the clinical characteristics for patients who received modafinil to promote wakefulness and improve
104 cognition, and describe the median change in GCS before and after modafinil therapy. The author also sought to
105 describe the safety, ICU course, and outcomes including duration of mechanical ventilation, ICU length of stay
106 (LOS), hospital LOS, and all-cause of mortality rate.

107 **2. Methods**

108

109 **2.1 Study design and setting:**

110 This was an observational, retrospective, case series performed at a single tertiary care center King Faisal
111 Specialist Hospital and Research Centre (KFSH & RC), Riyadh, the primary referral center in Saudi Arabia. During
112 the COVID-19 pandemic, ICU units were expanded and approximately ~141 COVID ICU beds were added, in
113 addition to approximately ~45 beds in non-COVID ICU units (medical, surgical, transplant/oncology ICUs). The
114 study was approved by the Research Ethics Committee and Clinical Research Committee. The patient's written
115 consent to publish was taken for each case included in the series. Data were collected and managed using
116 institutional Research Electronic Data Capture (REDCap). The inclusion criteria were 1) ICU patients 18 years and
117 older 2) admitted to COVID and non-COVID units between January 2017 and June 2020 3) ICU stay for at least 48
118 h, 4) started on modafinil during ICU stay for at least 48 h, and 5) required ventilatory support. Those who did
119 not receive modafinil or received modafinil for indications other than ICU wakefulness were excluded. The CARE
120 (CAse REport) guidelines checklist was followed in describing each case included in this study [33]. The trial
121 registered retrospectively at clinical trial. gov [ClinicalTrials.gov Identifier: NCT04751227]

122

123 **2.2 Variables and statistical approach:**

124 Patient demographic data including ICU admission diagnosis, ICU type, comorbidities, and other ICU support
125 [tracheostomy, renal replacement therapy (RRT), steroids, COVID-19 treatment regimen, and vasopressors] were
126 obtained from the electronic medical record (EMR). The status of ventilator use before and after modafinil
127 administration, modafinil initiation time in relation to ICU admission, dose and duration of treatment were also
128 recorded. Severity of illness was evaluated using Sequential Organ Failure Assessment (SOFA) and Acute
129 Physiology and Chronic Health Evaluation (APACHEII) scores. The worst value for baseline laboratory tests was
130 chosen. These data were collected within the first 24 h after admission to the ICU. If that data were not available,
131 then data closest to admission were recorded. Work up for decreased level of consciousness (LOC) was recorded
132 including metabolic abnormalities, neuroimaging [brain computed tomography (CT), and magnetic resonance
133 imaging (MRI)], electroencephalogram (EEG), lumbar puncture, and cerebrospinal fluid (CSF) analysis. The
134 findings of nerve conduction studies (NCS), electromyography (EMG), and other complications during ICU stay
135 were documented. The GCS 48 h before and 168 h (7 days) after modafinil therapy, ICU LOS, hospital LOS,
136 discharge disposition, duration of mechanical ventilation, and mortality rate were recorded. We defined
137 responders for GCS change as a 2 points increase from baseline post modafinil initiation up to 7 days. Duration
138 of mechanical ventilation was recorded as the number of calendar days from intubation to extubation or until
139 ICU discharge, or death whichever occurs first. All-cause mortality rate was reported at 28 and 90 days. The
140 documentation in the EMR was reviewed to identify the patients started on antipsychotics and possible adverse
141 drug reactions (ADRs) related to modafinil including nervousness, agitation, delirium, hypersensitivity, and drug
142 rash. Naranjo scale was used to evaluate the causality of ADRs and modafinil therapy [34].

143 Continuous variables were presented as mean \pm standard deviation (SD) or median (interquartile range [IQR]) as
144 appropriate, and categorical variables were presented as number and frequency (%). The changes in GCS was

145 examined graphically over time. Owing to the retrospective and exploratory nature of this case series, no sample
146 size justification is provided. Instead we wish to report all the patients meeting the inclusion criteria which might
147 be useful to other researchers who may want to combine these results with their own in a meta-analytic
148 approach. Descriptive statistical analysis was conducted using IBM SPSS Statistics, windows version 25.0 (IBM
149 Corp., Armonk, NY).

150 **3. Results**

151 **3.1. Patient characteristics**

152 A total of 8 patients who met the inclusion criteria were described in this case series. The demographics and clinical
153 characteristics are summarized in **Table 2**. The median patient age was 76 (IQR 64.75-80.25) years, 7 (87.5 %)
154 were men, 3 (37.5%) admitted to COVID ICU, and 5 (62.5%) admitted to non-COVID ICU. Regarding the
155 comorbidities, OSA was noted in 2 (25%), and ischemic stroke in 2 (25%). The median SOFA and APACHE II scores
156 were 9.5 (IQR 7.25-11) and 27.5 (IQR 19.5- 33), respectively. The median time from ICU admission to modafinil
157 administration was 11 (IQR 9-17) days. Seven patients (87.5%) started on modafinil 100 mg orally every morning
158 while one patient received 200 mg daily for a median duration of 4 days [IQR 3.25-5]. The main indication for
159 modafinil initiation was decreased LOC and altered mental status that potentially preclude successful extubation
160 or liberation from mechanical ventilation. All patients received vasopressors during the ICU stay, and 5 patients
161 (62.5%) started on RRT for pre-existing chronic kidney disease or acute kidney injury. All COVID-19 patients were
162 treated according to our institution protocol for antivirals and immunomodulatory therapies for possibility of
163 cytokine storm. One patient received 5 days of IVIG as part of COVID-19 regimen (patient #1) and one patient
164 received it for possible GBS (patient #8).

165

166 **3.2. Follow up and ICU complications**

167 **Table 3** illustrates the workup for decreased LOC during the ICU stay prior to modafinil initiation. Two patients
168 (25%) had initial neuroimaging that showed hemorrhagic stroke, and one (12.5%) had ischemic stroke with

169 hemorrhagic transformation; EEG was performed for 6 (75%) patients and none showed epileptic activity. The
170 cerebrospinal fluid (CSF) analysis was done in 4 patients (50%) and 3 patients showed evidence of nosocomial
171 meningitis that was treated with appropriate antimicrobials [patients # 5-7]. The EMG and NCS were positive in
172 1 patient (12.5%) for the critical illness myopathy – neuropathy [patient # 8].

173 Complications arising in the ICU included intra-abdominal infections in 2 (25%) [patients # 4,8], *Clostridium difficile*
174 infection [patients #2,7], endocarditis [patients # 7], cardiac arrest in 2 (25 %) [patients # 6, 8], pulmonary
175 embolism in 1 (12.5%) [patient #2], disseminated intravascular coagulation (DIC) in 1 (12.5%) [patient #2], heparin-
176 induced thrombocytopenia (HIT) in 1 (12.5%) [patient #2], and gastrointestinal bleeding (GIB) and hemorrhagic
177 shock in 3 (37.5%) which required massive transfusion [patients # 2, 4,8]. Antipsychotic drug [quetiapine] was
178 started for 2 patients (25%). No other ADRs were documented.

179

180 **3.3 Outcomes**

181 The median change of GCS 48 h before and 168 h after modafinil therapy is displayed in **Fig. 1**. Time 0 the time
182 modafinil was first administered. An improvement was noted in patients # 1, 3, 4, 5, 6. In patient 8, the GCS slightly
183 increased initially after modafinil administration then remains unchanged after that. Patient # 2 and 7, no
184 improvement was noted in GCS after modafinil therapy.

185 **Table 4** describes the clinical outcomes and patients' disposition. The median ratio of partial pressure of oxygen
186 and fraction of inspired oxygen (PO₂/FiO₂) prior to modafinil administration was 223.5 (IQR 175.75-265) which
187 changed slightly after administration, to a median of 195 (IQR 170-390). The median duration of mechanical
188 ventilation was 17.5 [IQR 15-31.75] days; 6 patients (75%) were alive after 28 days and 3 (37.5 %) were alive after
189 90 days. The median ICU stay was 28.5 (IQR 20.25-48) days, and the median hospital stay was 36.5 (IQR 26.75-
190 115.25) days. Tracheostomy was done in 5 patients (62.5%) and we were able to avoid it in one COVID-19 patient
191 who was subsequently liberated from mechanical ventilation and successfully extubated (patient #1).

192

193

194 4. Discussion

195 In our case series, we described our experience with modafinil for wakefulness in the critical care units including
196 COVID-19 patients at a tertiary care hospital. In majority of the cases, nonpharmacologic measures to
197 encourage a healthy sleep cycle were employed prior to modafinil initiation. Moreover, we addressed multiple
198 potential etiologies for altered mental status prior to modafinil initiation including primary CNS process,
199 metabolic derangements, hypoxemia or hypercarbia due to respiratory failure, renal or hepatic dysfunction,
200 nutritional deficiencies (e.g. thiamine) in patients with poor nutritional status, infection and sepsis induced
201 encephalopathy, medication effects [sedation required for prolonged intubation], EEG to rule out non-
202 convulsive seizure, lumbar puncture if the patient's neurological findings were not explained by above studies,
203 and NCS to rule out neuromuscular disorders that could preclude successful extubation. Although we cannot
204 state with certainty that modafinil was the primary reason for improvement of cognition function, the temporal
205 relationship between starting modafinil and patients' improvement makes it a potential contributing factor.

206 The use of modafinil in a population with neurological findings had been examined before and summarized in
207 table 1 [27-32]. The first trial examined the efficacy of modafinil in treating fatigue and EDS in individuals with
208 TBI [27]. This was a single-center, double-blind, placebo-controlled cross-over trial, where 53 participants were
209 randomly assigned to receive up to 400 mg of modafinil, or placebo. After adjusting for baseline scores and
210 period effects, there were no statistically significant differences between improvements seen with modafinil
211 and placebo on Fatigue Severity Scale (FSS) at wk 4 (-0.5 ± 1.88 ; $p = 0.80$) or wk 10 (-1.4 ± 2.75 ; $p = 0.61$). For
212 Epworth Sleepiness Scale (ESS) for daytime sleepiness, average changes were significantly greater with modafinil
213 than placebo at wk 4 (-1.2 ± 0.49 ; $p = 0.02$) but not at wk 10 (-0.5 ± 0.87 ; $p = 0.56$). Modafinil was safe and well
214 tolerated, although insomnia was reported significantly more often with modafinil than with placebo ($p = 0.03$).
215 Another trial in mild to severe TBI patients in ICU used lower dose of modafinil of 100-200 mg or placebo every
216 morning for 6 wk [28]. This prospective, double-blind, randomized, placebo-controlled pilot study was aimed at
217 studying the effect of daily modafinil on post traumatic EDS and fatigue. The EDS improved significantly in

218 patients with TBI receiving modafinil treatment, compared to the placebo group. Modafinil, however, had no
219 impact on posttraumatic fatigue. Clinically relevant side effects were not observed.

220 A systematic review for amantadine and modafinil as neuro-stimulants during post-stroke care identified 12,620
221 publications including 12 modafinil publications (n = 120 patients) [17, 29, 30]. Modafinil was initiated 170 (17,
222 496) days post-stroke, with initial and final daily doses of 100 (100, 350) mg/day and 200 (100, 350) mg/day,
223 respectively. The most common indication was fatigue for modafinil (n = 5/12; 42%). Only 1 randomized study
224 analyzing the effect of modafinil (8%; n = 21 patients) on acutely hospitalized or ICU patients, witnessed
225 improvement in neurocognitive function. The authors concluded that modafinil may improve cognitive and
226 functional recovery post-stroke, but higher quality data are needed to confirm this conclusion, especially in the
227 acute care setting.

228 Focusing on ICU setting, Gajewski *et al* published a case series of 3 non-ventilated patients in thoracic surgery
229 ICU without a prior diagnosis of any sleep disorder and receiving a dose of 200 mg modafinil each morning [31].

230 The primary outcome was to expedite recovery through early rehabilitation. The 1st case was 77-year-old male
231 with a medical history of small non-cancerous lung cells who was readmitted for respiratory distress requiring
232 intubation, then extubated and continued to require intermittent noninvasive ventilation for dyspnea and he
233 was not participating in physical therapy due to hypersomnolence. He was prescribed 200 mg modafinil every
234 morning for 13 d. At day 2, he was weaned on 3-L nasal cannula and made advances in rehabilitation. The 2nd
235 case was a 67-year-old male with a medical history of esophageal cancer. He was admitted to ICU for
236 management of pneumonia and sepsis and received washouts for gastro-pleural fistula. After his initial surgery,
237 he was noted to be extremely fatigued and expressing wishes to withdraw care. Modafinil 200 mg every morning
238 was started and on day 2, the patient was more engaged in his care. No side effects were noted throughout the
239 8 days course. The 3rd case was a 70-year-old male with a medical history of esophageal cancer was admitted to
240 the ICU for respiratory failure which was improved and eventually extubated. His rehabilitative status was
241 complicated by his overall lack of energy, and his waxing and waning mental status. Modafinil was started at a
242 dose of 100 -200 mg. At day 6, the patient did not need his home lorazepam 1.5 mg at night and he engaged

243 more in his care. The author concluded that modafinil was beneficial in the ICU owing to its effects on improving
244 sleep efficiency, adjusting circadian sleep-cycle disruption, and decreasing EDS which subsequently reduce
245 delirium, improve day-time cognition, improve wakefulness, and facilitate engagement with physical therapy
246 and rehab. Compared to those findings, our observations suggested that modafinil improves cognition and
247 increases GCS in 5 (62.5%) patients in our series, suggesting it might be reasonable for promoting wakefulness
248 in ICU patients especially in mechanically ventilated patients which have not been described in the prior case
249 series [31]. Moreover, we included more diverse cohort from transplant, surgical, and COVID-19 ICUs which had
250 not been reported in the prior literature [31,32]. Mechanically ventilated COVID-19 patients may require higher
251 doses of opioids and sedatives to mitigate ventilator-induced lung injury, and prevent self-extubation. Deep
252 levels of sedation may also require prior to initiation of neuromuscular blocking agents (NMB) in moderate-to-
253 severe acute respiratory distress syndrome (ARDS) [35]. All these factors could potentially delay the recovery of
254 neurocognitive function and increase risks of ICU acquired weakness particularly when corticosteroids are used
255 with aminosteroidal NMB [36]. However, clinicians should also be cognizant that COVID-19 patients are
256 predominately presented with hyperactive delirium, and agitation due to multiple factors including direct virus
257 invasion to CNS, prolonged mechanical ventilation, social isolation, and restricted family visitation [37].
258 Therefore, comprehensive assessment is warranted to identify those who might benefit from modafinil as
259 wakefulness agent prior to initiation of therapy. Moreover, the most common dose of modafinil that was used
260 in our series 100 mg oral once every morning with a median duration of 4 days and was fairly tolerated. Based
261 on published data, the usual dose of modafinil is 100-400 mg (starting dose 100-200 mg oral daily with a lower
262 dose recommended for patients with cardiovascular diseases and liver cirrhosis) [31, 32]. Therefore, a less ideal
263 response in term of GCS improvement was observed in patients # 2, 7, and 8 which might be due to inadequate
264 modafinil dose. Hence, a higher dose might be reasonable to use in these situations. Regarding the safety and
265 ADRs, we used the Naranjo scale for assessment of causality and a score of 0 to -1 indicated a doubtful causality
266 of ADRs and modafinil therapy in our series [34]. The ICU complications were most likely attributed to underlying
267 comorbidities.

268 Interestingly, modafinil prevented tracheostomy in one patient with COVID-19 (case 1) who was then
269 successfully extubated. A previous report showed that patients with COVID 19 who required prolonged
270 mechanical ventilation had a high mortality rate. Therefore, tracheostomy might be considered when prolonged
271 mechanical ventilation is anticipated [38]. On the other hand, studies showed that tracheostomy carries
272 significant risk of viral transmission to the healthcare workers [39]. Hence, preventing tracheostomy provided
273 advantages including shortening duration of critical care resource use (ventilators) and ICU length of stay during
274 COVID-19 outbreak, and minimizing aerosolization risks associated with this procedure for healthcare workers.
275 Furthermore, 2 patients (case # 5, and 7) has a neuroimaging that showed hemorrhagic stroke, 1 patient (case
276 #6) showed ischemic stroke with hemorrhagic transformation, a population which had not been assessed for
277 modafinil treatment in the prior literature [17, 27-32]. Moreover, 2 (25 %) of the patients (case #4, and 5) had
278 a history of OSA. We speculated that the observed improvements in cognition and GCS of these patients
279 possibly were related to enhanced nocturnal sleep based on the drug mechanism of action; however, further
280 evaluation is still needed. The 28 d all-cause mortality rate in our series was 2 (25 %) and 90 d all-cause mortality
281 rate was 5 (62.5%) and this is possibly expected as we are a tertiary care hospital. Therefore, it is likely that our
282 patients were sicker, as the APACHEII and SOFA scores suggest that these data were derived from a cohort of
283 critically ill patients. This is comparable to the mortality rate in patients admitted to the ICU with severe sepsis
284 and shock [40-42].

285 Our study limitations were small sample size, single institution experience, retrospective and observational in
286 nature, and lack of a control group which precludes causal interpretations. Similar to other observational
287 studies, our findings can be biased by confounding from unmeasured factors that influence cognitive function
288 and recovery such as the effect of physiotherapy and rehabilitation. It is also plausible that the increasing trend
289 in GCS over time was largely owing to the result of reduced exposure to other sedatives and analgesics and
290 spontaneous recovery. Moreover, patient-family interaction has a great impact in patient recovery as shown in
291 the recent report [43, 44]. In our series, the intensivist on service had the patient described in case 1 interact
292 with the patient's family through video calling, which likely uplifted his spirit and played a potential role in his

293 recovery. Additionally, the small sample size prohibited us from performing statistical analysis to assess and
294 adjust for confounders or perform analysis of what factors might be associated with response or lack thereof.
295 This may have led to an overestimation or underestimation of modafinil effect for wakefulness in the critical
296 care unit [45]. As is always the case with observation type study, association does not prove causality, but there
297 are reasonable data showing that modafinil might have potential benefits when administered to certain critically
298 ill patients especially those who appear hypoactive, lethargic, and depressed and particularly when conservative
299 treatment has failed, which provides biological plausibility [17, 27-32]. Its daily cost is insignificant compared
300 with the high cost of an extended ICU stay although it is difficult to conclude from our experience that patients'
301 length of ICU stay was shortened. Nonetheless, we felt that it is important to report our experience to help
302 rationalize and understand the role of neurostimulants to promote arousal and wakefulness in the ICU which
303 subsequently facilitate self-expression, accelerate recovery, increase participation in physiotherapy and
304 ambulation, hastening liberation from the ventilatory support, and decrease ICU-related complications such as
305 DVT, and ICU-acquired delirium.

306 Based on our observations of these patients, the known effects of modafinil, its safety profile, and the published
307 experiences of others, we believe that modafinil might has potential benefits and that the consequences of
308 delayed patient recovery and a prolonged ICU stay may outweigh the risks of potential modafinil side effects.
309 Although we cannot state with certainty that modafinil improves cognition function and GCS in our series, it
310 seems that the timing of drug administration in concert with the putative benefits of the medication makes it a
311 plausible conclusion.

312 There are many unanswered questions that we believe would be a good starting point for a larger randomized
313 controlled trial to substantiate the ideal time of modafinil initiation, identify the population that most likely
314 benefit from therapy, define the optimal drug dose and duration, and identify the role of a combination therapy
315 and its impact on clinical outcomes. Future studies with appropriate sample size, adequate power are needed
316 to better describe its role in the ICU patients post hemorrhagic stroke. Additionally, the impact of modafinil
317 therapy on overall ICU outcomes, such as mortality, duration of mechanical ventilation, and ICU length of stay

318 should be evaluated in future prospective studies. Lastly, further studies are needed to provide more insights
319 and understand modafinil use in critically ill COVID-19 patients. However, in this pandemic setting, evidence of
320 some physiological safety and possible benefit might be considered for hypothesis generation, as shown in our
321 series.

322 **5. Conclusion**

323 Cognitive improvement after critical illness is complex. In our case series, we reviewed the literature and
324 described our center's experience for modafinil use for wakefulness in the ICU ventilated patients including
325 COVID-19 patients. Based on our observations of these patients, the known effects of modafinil, and its safety
326 profile, we believe that modafinil might has potential benefits when administered to certain critically ill patients
327 especially those who appear hypoactive, and lethargic after comprehensive assessment of potential etiologies
328 for altered mental status. Though our observations are intriguing, they result from uncontrolled, retrospective
329 chart review and confounding bias is likely which preclude definitive statements. Nevertheless, this initial
330 experience is promising and may provide preliminary evidence and hypothesis warrant to be assessed in
331 randomized controlled trials.

332 **Tables and Figure**

333 **Table 1** : Trials on modafinil use in neuro and ICU population

334 **Table 2**: Demographics and baseline characteristics

335 **Table 3**: Workup for decreased level of consciousness (LOC) and complications during ICU stay

336 **Table 4**: Clinical outcome and patients disposition

337 **Figure 1**: Trend of Glasgow Coma Scale (GCS) over time before and after modafinil

338 **Figure Legend**: The graphs present the median change of GCS 48 h before and 168 h (7 days) after
339 modafinil therapy. The GCS ranges from 3 to 15, with higher scores indicating a higher level of
340 consciousness. Time 0 the time modafinil was first administered . Improvement was noted on patient #
341 1, 3, 4, 5, 6. No improvement was noted for patient # 2, 7. Patient # 8 received modafinil twice: first trial
342 was 100 mg oral every morning for 5 days [patient 8 a] and the second trial was of 100 mg oral every

343 morning for 6 days [patient 8 b]. In both scenarios, the GCS slightly increased initially after modafinil
344 administration then remains unchanged after that.

345 **Figure Abbreviation:** GCS : Glasgow Coma Scale

346 **Supplemental Digital Content**

347 **Table S1** Selected neuro-stimulants use in neuro-ICU

348

349

350 **Acknowledgment**

351 We thank the ICU physicians, ICU nurses, ICU respiratory therapists, ICU physiotherapists, ICU satellite
352 pharmacists, and ICU clinical pharmacists of KFSH&RC for their efforts to save the life of ICU patients and their
353 braveness in fighting against COVID-19 pandemic. We appreciate pharmacy automation team effort and their
354 help to identify the ICU cases for our series [Maher Mominah, and Rania Al-Jaber]. We are also thankful for Hala
355 Khalil, PhD, Department of Biostatistics, Epidemiology and Scientific Computing for providing help in biostatistical
356 part of manuscript.

357

358 **Authors contribution**

359 MA: proposed the study, led the manuscript writing and did the data collection. MG: proposed the idea, gave
360 approval for modafinil as a sleep medicine consultant, reviewed and edited the manuscript. MA, MB, AB,
361 MG made substantial contributions to the concept and design of this project and has further participated in the
362 analysis and interpretation of the data. TD, EK: reviewed and edited the final version of the manuscript. All
363 authors participated in the care of the patients, revised the manuscript for important intellectual content and
364 approved the final version to be published. We confirmed that the authorship followed the uniform
365 requirements for manuscripts submitted to biomedical journals.

366

367 **Funding:**

368 This research did not receive any specific grant from funding agencies in the public, commercial, or not-
369 for-profit sectors.

370 **Declarations of interest:**

371 The authors declare that they have no known competing financial interests or personal relationships that
372 could have appeared to influence the work reported in this paper.

373 **Availability of data and material**

374 The datasets used and analyzed during the current report are available from the corresponding
375 author on reasonable request.

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392 **List of Abbreviation:** acute kidney injury (AKI), acute respiratory distress syndrome (ARDS), adverse drug
393 reactions (ADRs), cerebrospinal fluid (CSF), computed tomography (CT), coronavirus disease 2019 (COVID-19),
394 central nervous system (CNS), continuous renal replacement therapies (CRRT), deep vein thrombosis (DVT),
395 diabetes type 2 (DM-2), disseminated intravascular coagulation (DIC), do-not-resuscitate (DNR), end-stage renal
396 disease (ESRD), external ventricular drain (EVD), electroencephalogram (EEG), electromyogram and nerve
397 conduction study (EMG and NCS), emergency department (ED), epworth sleepiness scale (ESS), excessive daytime
398 sleepiness (EDS), fatigue severity scale (FSS), Glasgow Coma Scale (GCS), Guillian Barré syndrome (GBS), gamma-
399 aminobutyric acid (GABA), gastrointestinal bleeding (GIB), heparin-induced thrombocytopenia (HIT), hepatitis C
400 virus (HCV), heart failure with preserved ejection fraction (HFpEF), hemodialysis (HD), intensive care unit (ICU),
401 intravenous immunoglobulin (IVIG), intracranial bleeding (ICH), intraventricular hemorrhage (IVH), King Faisal
402 Specialist Hospital and Research Centre (KFSH&RC), level of consciousness (LOC), lumbar puncture (LP), Middle
403 East respiratory syndrome (MERS), myocardial infarction (MI), minimally conscious state (MCS), middle cerebral
404 artery (MCA), magnetic resonance imaging (MRI), neuromuscular blocking agents (NMB), operating room (OR),
405 Pain, Agitation/ Sedation, Delirium, Immobility, and Sleep Disruption (PADIS), renal replacement therapy (RRT),
406 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subarachnoid hemorrhage (SAH), traumatic brain
407 injury (TBI), vegetative state (VS).

408

409

410

411

412

413

414

415 **References**

- 416 1. Wijdicks EFM. Metabolic encephalopathy: behind the name. *Neurocrit Care*. 2018;29:385–7.
417 doi: 10.1007/s12028-017-0497-1.
- 418 2. Elías MN, Munro CL, Liang Z, Calero K, Ji M. Sleep and Intensive Care Unit-Acquired Weakness in
419 Critically Ill Older Adults. *Dimens Crit Care Nurs*. 2019 Jan/Feb;38(1):20-28. doi:
420 10.1097/DCC.0000000000000335.
- 421 3. Devlin JW, Skrobik Y, Gélinas C et al. Clinical practice guidelines for the prevention and management
422 of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. *Crit*
423 *Care Med*. 2018;46:e825–73. DOI: 10.1097/CCM.00000000000003299
- 424 4. Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. *J Exp*
425 *Med*. 2005;202:415–24. DOI: 10.1084/jem.20050828
- 426 5. Paterson RW, Brown RL, Benjamin L, et al. The emerging spectrum of COVID-19 neurology: clinical,
427 radiological and laboratory findings. *Brain*. 2020;8. DOI: 10.1093/brain/awaa240
- 428 6. Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus
429 Disease 2019 in Wuhan, China. *JAMA Neurol*. 2020;77(6):683–690.
430 doi:10.1001/jamaneurol.2020.1127
- 431 7. Helms J, Kremer S, Merdji H et al. Neurologic features in severe SARS-CoV-2 infection. *N Engl J*
432 *Med*. 2020 June 4;382:2268–70. DOI: 10.1056/NEJMc2008597.
- 433 8. Toscano G, Palmerini F, Ravaglia S et al. Guillain-Barré syndrome associated with SARS-CoV-2. *N*
434 *Engl J Med*. 2020 June 25;382:2574–6. DOI: 10.1056/NEJMc2009191. Epub April 17 2020.
- 435 9. De Jonghe B, Sharshar T, Lefaucheur JP et al. Paresis acquired in the intensive care unit: a prospective
436 multicenter study. *JAMA*. 2002;288:2859–67. doi: 10.1001/jama.288.22.2859.
- 437 10. Stevens RD, Dowdy DW, Michaels RK, Mendez-Tellez PA, Pronovost PJ, Needham DM. Neuromuscular
438 dysfunction acquired in critical illness: a systematic review. *Intensive Care Med*. 2007 Nov;33(11):1876-
439 91. doi: 10.1007/s00134-007-0772-2.

- 440 11. Tsai L, Hsieh S, Chao C, et al. Neuromuscular Disorders in Severe Acute Respiratory Syndrome. Arch
441 Neurol. 2004;61(11):1669–1673. doi:10.1001/archneur.61.11.1669.
- 442 12. Algahtani H, Subahi A, Shirah B. Neurological complications of Middle East
443 respiratory syndrome coronavirus: A report of two cases and review of the literature. *Case Rep Neurol*
444 *Med.* 2016;2016:3502683. doi: 10.1155/2016/3502683
- 445 13. Bleck TP. How critical illness affects the brain ...and vice versa. *Crit Care Med.* 2018;46:465–70. doi:
446 10.1097/CCM.0000000000002944.
- 447 14. Meythaler JM, Brunner RC, Johnson A, Novack TA. Amantadine to improve neurorecovery in traumatic
448 brain injury-associated diffuse axonal injury: a pilot double-blind randomized trial. *J Head Trauma*
449 *Rehabil.* 2002;17:300–13. doi: 10.1097/00001199-200208000-00004
- 450 15. Saniova B, Drobny M, Kneslova L, Minarik M. The outcome of patients with severe head injuries
451 treated with amantadine sulphate. *J Neural Transm.* 2004;111:511–4. doi: 10.1007/s00702-004-0112-
452 4.
- 453 16. Giacino JT, Whyte J, Bagiella E et al. Placebo-controlled trial of amantadine for severe traumatic brain
454 injury. *N Engl J Med.* 2012;366:819–26. doi: 10.1056/NEJMoa1102609
- 455 17. Gagnon DJ, Leclerc AM, Riker RR et al. Amantadine and modafinil as neurostimulants during post-
456 stroke care: A systematic review. *Neurocrit Care.* 2020;12:020–00977. doi: 10.1007/s12028-020-
457 00977-5
- 458 18. Chollet F, Tardy J, Albucher JF et al. Fluoxetine for motor recovery after acute ischaemic stroke
459 (FLAME): a randomised placebo-controlled trial. *Lancet Neurol.* 2011;10:123–30. doi: 10.1016/S1474-
460 4422(10)70314-8.
- 461 19. FOCUS Trial Collaboration. Effects of fluoxetine on functional outcomes after acute stroke (Focus): a
462 pragmatic, double-blind, randomised, controlled trial. *Lancet.* 2019;393:265–74. doi: 10.1016/S0140-
463 6736(18)32823-X

- 464 20. AFFINITY Trial Collaboration. Safety and efficacy of fluoxetine on functional outcome after acute stroke
465 (AFFINITY): a randomised, double-blind, placebo-controlled trial. *Lancet Neurol.* 2020;19:651–660.
466 doi: 10.1016/S1474-4422(20)30207-6
- 467 21. Moein H, Khalili HA, Keramatian K. Effect of methylphenidate on ICU and hospital length of stay in
468 patients with severe and moderate traumatic brain injury. *Clin Neurol Neurosurg.* 2006;108:539–42.
469 DOI: 10.1016/j.clineuro.2005.09.003
- 470 22. Johansson B, Wentzel AP, Andréll P, Odenstedt J, Mannheimer C, Rönnbäck L. Evaluation of dosage,
471 safety and effects of methylphenidate on post-traumatic brain injury symptoms with a focus on mental
472 fatigue and pain. *Brain Inj.* 2014;28:304–10. doi: 10.3109/02699052.2013.865267
- 473 23. Johansson B, Wentzel AP, Andréll P, Mannheimer C, Rönnbäck L. Methylphenidate reduces mental
474 fatigue and improves processing speed in persons suffered a traumatic brain injury. *Brain*
475 *Inj.* 2015;29:758–65. DOI: 10.3109/02699052.2015.1004747
- 476 24. Martinsson L, Hårdemark H, Eksborg S. Amphetamines for improving recovery after stroke. *Cochrane*
477 *Database Syst Rev.* 2007;24:CD002090. doi: 10.1002/14651858.CD002090.pub2.
- 478 25. Schuster C, Maunz G, Lutz K, Kischka U, Sturzenegger R, Ettlín T. Dexamphetamine improves upper
479 extremity outcome during rehabilitation after stroke: a pilot randomized controlled trial. *Neurorehabil*
480 *Neural Repair.* 2011;25:749–55. doi: 10.1177/1545968311405674.
- 481 26. Ballon JS, Feifel D. A systematic review of modafinil: potential clinical uses and mechanisms of action.
482 *J Clin Psychiatry.* 2006;67:554–66. doi: 10.4088/jcp.v67n0406.
- 483 27. Jha A, Weintraub A, Allshouse A, et al. A randomized trial of modafinil for the treatment of fatigue and
484 excessive daytime sleepiness in individuals with chronic traumatic brain injury. *J Head Trauma*
485 *Rehabil.* 2008;23:52–63. doi: 10.1097/01.HTR.0000308721.77911.ea.
- 486 28. Kaiser PR, Valko PO, Werth E, et al. Modafinil ameliorates excessive daytime sleepiness after traumatic
487 brain injury. *Neurology.* 2010;75:1780–5. doi: 10.1212/WNL.0b013e3181fd62a2.

- 488 29. Poulsen MB, Damgaard B, Zerahn B, Overgaard K, Rasmussen RS. Modafinil May Alleviate Poststroke
489 Fatigue: A Randomized, Placebo-Controlled, Double-Blinded Trial. *Stroke*. 2015 Dec;46(12):3470-7.
490 doi: 10.1161/STROKEAHA.115.010860
- 491 30. Bivard A, Lillicrap T, Krishnamurthy V. MIDAS (modafinil in debilitating fatigue after stroke):
492 A randomized, double-blind, placebo-controlled, cross-over trial. *Stroke*. 2017;48:1293–8. doi:
493 10.1161/STROKEAHA.116.016293.
- 494 31. Gajewski M, Weinhouse G. The use of modafinil in the Intensive Care Unit. *J Intensive Care*
495 *Med*. 2016;31:142–5. doi: 10.1177/0885066615571899.
- 496 32. Mo Y, Thomas MC, Miano TA. Effect of modafinil on cognitive function in Intensive Care Unit patients:
497 A retrospective cohort study. *J Clin Pharmacol*. 2018;58:152–7. doi: 10.1002/jcph.1002
- 498 33. Gagnier et al.: The CARE guidelines: consensus-based clinical case reporting guideline development.
499 *Journal of Medical Case Reports* 2013 7:223. doi: 10.7453/gahmj.2013.008
- 500 34. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug
501 reactions. *Clin Pharmacol Ther*. 1981;30:239–45. doi: 10.1038/clpt.1981.154.
- 502 35. Ammar MA, Sacha GL, Welch SC, et al. Sedation, Analgesia, and Paralysis in COVID-19 Patients in the
503 Setting of Drug Shortages. *J Intensive Care Med*. 2020 Aug 26:885066620951426. doi:
504 10.1177/0885066620951426.
- 505 36. Mefford B, Donaldson JC, Bissell BD. To Block or Not: Updates in Neuromuscular Blockade in Acute
506 Respiratory Distress Syndrome. *Ann Pharmacother*. 2020 Sep;54(9):899-906. doi:
507 10.1177/1060028020910132.
- 508 37. Kotfis, K., Williams Roberson, S., Wilson, J.E. et al. COVID-19: ICU delirium management during SARS-
509 CoV-2 pandemic. *Crit Care* 24, 176 (2020). doi: 10.1186/s13054-020-02882-x
- 510 38. Auld S, Caridi-Scheible M, Blum JM, et al. ICU and ventilator mortality among critically ill adults with
511 Coronavirus Disease 2019. *Crit Care Med*. 2020 May 26 . doi: 10.1097/CCM.0000000000004457 .

- 512 39. Shiba T, Ghazizadeh S, Chhetri D, St John M, Long J. Tracheostomy considerations during the COVID-
513 19 pandemic. *OTO Open*. 2020;4:2473974X20922528. DOI: 10.1177/2473974X20922528
- 514 40. Mohamed AKS, Mehta AA, James P. Predictors of mortality of severe sepsis among adult patients in
515 the medical Intensive Care Unit. *Lung India*. 2017;34:330–5. DOI: 10.4103/lungindia.lungindia_54_16
- 516 41. Woolf SH, Chapman DA, Sabo RT, Weinberger DM, Hill L. Excess deaths from COVID-19 and
517 other causes, March-April 2020. *JAMA*. 2020. DOI: 10.1001/jama.2020.11787
- 518 42. Quah P, Li A, Phua J. Mortality rates of patients with COVID-19 in the intensive care unit: a systematic
519 review of the emerging literature. *Crit Care*. 2020;24:285. doi: 10.1186/s13054-020-03006-1
- 520 43. Devlin JW, O’Neal HR Jr, Thomas C, et al. Strategies to optimize ICU liberation (A to F)
521 bundle performance in critically ill adults with coronavirus Disease 2019. *Critical Care*
522 *Explorations*. 2020 June 12;2:e0139. DOI: 10.1097/CCE.0000000000000139.
- 523 44. Pun BT, Balas MC, Barnes-Daly MA, et al. Caring for critically ill patients with the ABCDEF bundle:
524 results of the ICU Liberation Collaborative in over 15,000 adults. *Crit Care Med*. 2019;47:3–14. DOI:
525 10.1097/CCM.00000000000003482
- 526 45. Fanaroff AC, Califf RM, Harrington RA. Randomized Trials Versus Common Sense and Clinical Observation:
527 JACC Review Topic of the Week. *J Am Coll Cardiol*. 2020;76:580–589. doi:10.1016/j.jacc.2020.05.069
- 528

Figure 1: Trend of Glasgow Coma Scale (GCS) over time before and after modafinil




Table 1: Trials on modafinil use in neuro and ICU population

Study	Patient population	Outcomes	Regimen	Results
Jha <i>et al.</i> Double – blind placebo controlled cross over (2008)/ n= 53 [27]	Moderate – Severe TBI	Fatigue Severity Scale (FSS) and daytime sleepiness (Epworth Sleepiness Scale, ESS) at wk 4 and wk 10	Modafinil titrated to 400 mg/day or placebo for 10 wk	Clear benefit from modafinil was not seen at wk 4 or wk 10
Kaiser <i>et al.</i> Prospective, double blind, randomized, placebo controlled (2010)/ n= 20 [28]	Mild to severe TBI patients in ICU	FSS and ESS at baseline and after 6 wk	Modafinil 100-200 mg or placebo every morning for 6 wk	Modafinil improved excessive daytime sleepiness but not fatigue
Poulsen <i>et al.</i> Double blinded, placebo controlled (2015)/ n= 41 [29]	Ischemic stroke with modified Rankin Scale score of ≤3 before admission	Fatigue at 90 d (multidimensional fatigue inventory)	Modafinil 400 daily or placebo for 90 d and started 1-14 d post stroke	No significant differences between the 2 groups
Bivard A <i>et al.</i> Randomized, double blind, placebo- controlled, crossover MIDAS trial (2017)/ n = 36 [30]	Ischemic stroke with multi-dimensional fatigue inventory score of ≥60	Fatigue (multidimensional fatigue inventory)	Modafinil 200 mg daily or placebo for 6 wk, 1 wk washout, started at least 3 mo post stroke	Modafinil decreased fatigue
Gagnon DJ <i>et al.</i> systematic review for amantadine and modafinil (2020)/ n= 120 [17]	Post- stroke	Cognitive and functional recovery	Modafinil 170 days post-stroke. Daily doses of 100- 200 mg/day	Modafinil may improve cognitive and functional recovery post-stroke, but higher quality data are needed
Gajewski <i>et al.</i> Case series (2015) / n=3 [31]	Non-ventilated patients in thoracic surgery ICU	Increase patient wakefulness, and enable a more restful sleep during the night	200 mg in the first 2 cases and 100 mg in the 3rd case increased later to 200 mg	All 3 pts more engaged in their care and made advances in rehabilitation . No side effect was observed
Yoonsun <i>et al.</i> retrospective cohort study (2017)/ n= 60 [32]	60 ICU patients with ventilatory support [medical, surgical, neuro ICU]	Requirements of opioids and sedatives, lowest and average scores of the GCS and SAS during 48 h before and after modafinil	median modafinil dose 170 mg with median duration of 9 d	Modafinil resulted in small, nonsignificant increase in GCS by 0.34 points after controlling for age, baseline severity of illness, and changes in sedation and analgesia over time (95% CI, -0.34 to 0.73 points; p = 0.0743)

Study	Patient population	Outcomes	Regimen	Results
Current study, observational case series (2020) / n= 8	8 ICU intubated patients [3 COVID-19 ICU, 4 surgical ICU, 1 transplant ICU]	Clinical characteristics, median change in GCS 48 h before and 168 h after modafinil	Modafinil 100-200 mg median duration 4 days	GCS improvement was noted on 5 patients (62.5%)

Table Footnote

Abbreviation: EDS: excessive daytime sleepiness, GCS: Glasgow Coma Scale, ICU: intensive care unit,

MIDAS: Modafinil in Debilitating Fatigue After Stroke, n: sample size, SAS: Riker Sedation-Agitation Scale,

TBI: traumatic brain injury

Table 2: Demographics and baseline characteristics

Patient characteristics	Value
Sex , male (n, %)	7 (87.5)
Age	
Median (IQR), years	76 (64.75-80.25)
Comorbidities (n, %)	
Heart failure	2 (25)
Atrial fibrillation	4 (50)
Hypertension	6 (75)
Diabetes type 2	5 (62.5)
Ischemic stroke	2 (25)
Seizure	1 (12.5)
Dyslipidemia	2 (25)
Chronic kidney disease	2 (25)
Below knee amputation	1 (12.5)
Hepatitis C virus	1 (12.5)
Obstructive sleep apnea	2 (25)
Osteoarthritis	1 (12.5)
Bilateral knee replacement	1 (12.5)
Solid organ transplant (kidney)	1 (12.5)
Liver cirrhosis secondary to NASH	1 (12.5)
Rheumatic heart disease	1 (12.5)
Mechanical mitral valve replacement	1 (12.5)
Type of ICU (n, %)	
COVID-19 ICU	3 (37.5)
Surgical ICU	4 (50)*
Transplant ICU	1 (12.5)
Diagnosis during ICU admission (n, %)	
Hypoxemic respiratory failure secondary COVID-19	1 (12.5)
Transferred from outside hospital with COVID-19 pneumonitis †	2 (25)
OR post exploratory laparotomy and small bowel resection	1 (12.5)
Surgical evacuation of intraventricular bleeding	1 (12.5)
Interventional thrombectomy for left internal carotid artery thrombosis	1 (12.5)
Right frontal EVD insertion Intracranial bleed	1 (12.5)
Post living related liver transplant	1 (12.5)
SOFA score	
Median (IQR)	9.5 (7.25-11)
APACHE II score	
Median (IQR)	27.5 (19.5 -33)
Modafinil dose (n, %)	

Patient characteristics	Value
100 mg oral every morning	7 (87.5)
100 mg oral every 12 hours	1 (12.5)
Modafinil duration	
Median (IQR), days	4 (3.25-5)
Modafinil start time in relation to ICU admission (days)	
Median (IQR), days	11 (9-17)
ICU medications and support (n, %)	
Vasopressors	8 (100)
Steroids	7 (87.5)
Renal replacement therapy (RRT)	5 (62.5)
Tocilizumab	1 (12.5)
Azithromycin	3 (37.5)
Hydroxychloroquine	3 (37.5)
Ribavirin	1 (12.5)
Intravenous immunoglobulin (IVIG)	2 (25)
Convalescent plasma	1 (12.5)
Antibiotics per infectious diseases team	5 (62.5)
Anti-epileptics	3 (37.5)
Nimodipine	1 (12.5)
Immunosuppressants	1 (12.5)
Antipsychotic: quetiapine	2 (25)

Table Footnote

* 3 patients (37.5 %) were neurosurgical ICU

† One patient transferred intubated from outside hospital (patient #2), and one transferred on nasal cannula from outside hospital and intubated at our institution (patient #3)

Abbreviation: APACHE: Acute Physiology and Chronic Health Evaluation, COVID-19: Coronavirus disease, EVD: External Ventricular Drain, NASH: Nonalcoholic steatohepatitis, SOFA: Sequential Organ Failure Assessment

Table 3: workup for decreased level of consciousness (LOC) and complications during ICU stay

Workup and complications	Value
Metabolic abnormalities prior to modafinil starts (n, %)	
AKI	4 (50)
ALF	6 (75)
Hypoglycemia	0 (0)
Initial neuroimaging (n, %)	
CT Brain	6 (75)
MRI brain	2 (25)
Time of initial neuroimaging (n, %)	
Day 1 of ICU admission	3 (37.5)
Day 2 of ICU admission	1 (12.5)
Day 4 of ICU admission	1 (12.5)
Day 5 of ICU admission	1 (12.5)
Other *	3 (37.5)
Initial neuroimaging findings	<p>Patient # 2,3,4: no evidence of acute intracranial insult</p> <p>Patient #1: Stigmata of age related severe microangiopathic ischemic changes with multiple scattered areas of encephalomalacia</p> <p>Patient #5: Post-surgical changes from recent evacuation of the right frontal hematoma with extensive IVH and active hydrocephalus</p> <p>Patient #6: Status post mechanical thrombectomy with interval development of left basal ganglia and intraventricular hemorrhage. Interval progression of the left MCA territory acute infarction with diffuse hypo attenuation and cytotoxic edema</p> <p>Patient #7: evidence of SAH within supratentorial and infratentorial regions with IVH associated with slight interval progression of hydrocephalus</p> <p>Patient #8: Small left frontal and right occipital acute/subacute infarcts with associated minimal punctate blood staining in the left frontal lobe. New small bilateral parietal microhemorrhages</p>
Repeated neuroimaging (n, %)	
None	4 (50)
CT brain	3 (37.5)
MRI brain	0
Time of repeated neuroimaging (n, %)	
Day 3 of ICU admission	1 (12.5)
Day 5 of ICU admission	1 (12.5)
Day 7 of ICU admission	2 (25)
Other [§]	2 (25)
Repeated Neuroimaging findings	Patient #2: No CT evidence of acute intracranial abnormality

Workup and complications	Value
	Patient #5: Status post right frontal craniotomy for evacuation of right frontal IPH and IVH with the placement of two drains. Interval evolution of right frontal IPH and IVH and slight decrease in ventricular dilatation.
	Patient #6: post-surgical changes from decompressive craniectomy and evacuation of basal ganglia hematoma with large left ACA/MCA territory infarction. Interval worsening of the rightward midline shift of 1.1 cm. Interval placement of the left frontal EVD with interval improvement in the size of the right lateral ventricle.
	Patient #7 Day 8: Several probable embolic infarcts in the right centrum ovale and corpus callosum, mild interval improvement of the SAH, no significant interval change of the IVH and ventricular dilatation.
	Patient #7 Day 13: Status post right frontal burr hole for insertion of EVD. No change in ventricular size. Signs of subacute IVH with no evolution of previously noted hemorrhage layering along occipital horns
	Patient #7 Day 25: Interval removal of right EVD, interval decrease of the IVH, with improvement of hydrocephalus, no new hemorrhage or acute abnormality
EEG (n, %)	6 (75)
EEG finding of seizure activity (n, %)	0 (0)
Lumbar puncture and CSF analysis (n, %)	4 (50)
EMG and NCS (n, %)	1 (12.5)
EMG and NCS finding: critical illness myopathy – neuropathy (n, %)	1 (12.5)
Complication during ICU stay (n, %)	
Nosocomial meningitis	3 (37.5)
Intra-abdominal infections	2 (25)
Other infections	5 (62.5)
Cardiac arrest	2 (25)
Pulmonary embolism	1 (12.5)
DIC	1 (12.5)
HIT	1 (12.5)
GIB	3 (37.5)
Hemorrhagic shock	1 (12.5)

Table Footnote

* Others: Day 15 (patient #1), day 8 (patient #3), 4 months (patient #8) of ICU admission

§ Others: Day 11 (patient #5), Day 8, day 13 and day 25 (patient #7) of ICU admission

Abbreviation: AKI: acute kidney injury, ALF: acute liver failure, ACA: anterior cerebral artery, CSF: cerebrospinal fluid, CT: computed tomography, DIC : disseminated intravascular coagulation, EEG: electroencephalogram, EVD: external ventricular drain, EMG and NCS: electromyogram and nerve conduction study, GIB: gastrointestinal bleeding, HIT: heparin-Induced thrombocytopenia, IPH: intraparenchymal hemorrhage, IVH: intraventricular hemorrhage, MRI: magnetic resonance imaging, MCA: middle cerebral artery, SAH: subarachnoid hemorrhage

Table 4: Clinical outcomes and patients disposition

Clinical outcome	Value
MV setting prior to start Modafinil	
FIO2	
Median (IQR)	0.33 (0.29-0.39)
PEEP	
Median (IQR), cmH2O	8 (5.25-9.5)
PaO2/ Fio2	
Median (IQR)	223.5 (175.75-265)
MV mode (n, %)	
PCV	2 (25)
PS	2 (25)
PRVC	2 (25)
Alternating PCV/PS	2 (25)
A/C	2 (25)
MV setting 48 hours after Modafinil	
FIO2	
Median (IQR)	0.30 (0.25-0.40)
PEEP	
Median (IQR), cmH2O	8 (5-9)
PaO2/ Fio2	
Median (IQR)	195 (170-390)
MV mode (n, %)	
PCV	2 (25)
PS	2 (25)
PRVC	2 (25)
Alternating PCV/PS	1 (12.5)
A/C	0
Duration of MV	
Median (IQR), days	17.5 (15-31.75)
Tracheostomy (n, %)	5 (62.5)
ICU length of stay	
Median (IQR) ,days	28.5 (20.25-48)
Hospital length of stay	
Median (IQR) ,days	36.5 (26.75-115.25)
28-days all-cause mortality (n, %)	2 (25)

Clinical outcome	Value
90-days all-cause mortality (n, %)	5 (62.5)

Table Footnote

Abbreviation: AC: assist-control mode, FiO2: fraction of inspired oxygen, MV: mechanical ventilation, PaO2: partial pressure of oxygen, PEEP: positive end-expiratory pressure, PCV: pressure control ventilation, PS: pressure support, PRVC: pressure-regulated volume control